Roche’s Genentech has signed a global licensing agreement with SanegeneBio to advance one of the China-based biotech’s RNAi programs.
Per the deal, SanegeneBio will receive a $200 million upfront payment and will be eligible to receive development and commercialization milestone payments, totaling up to $1.5 billion, plus tiered royalties.
The agreement grants Genentech exclusive worldwide rights to develop and commercialize SanegeneBio’s program — the specifics of which have not been revealed. SanegeneBio will be responsible for early development activities and Genentech will subsequently lead all future clinical development and commercialization activities.
SanegeneBio's proprietary RNAi platform includes novel chemistries and delivery technologies that can be utilized to generate potential breakthrough siRNA medicines for multiple disease areas.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!